27 results for "Rangi Kandane-Rathnayake"
Showing 1–20 · 0.31 seconds · RSS
-
Journal Article
Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study
Abstract Background The utility of generic health-related quality of life (HRQoL) questionnaires in patients with systemic lupus erythematosus (SLE) is uncertain. We compared the performance of generic (SF36) and specific (SLEQOL) HRQoL surveys by examining their associations with the Global Rating…
-
Journal Article
Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data
Objective Outcome measures used in SLE randomised controlled trials (RCTs) have impeded trial success and drug approval. In an ongoing global project to develop a novel outcome measure for SLE RCTs, a ‘core set’ of domains with which to determine treatment response was chosen via consensus. We…
-
Journal Article
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
Objectives Type 1 interferon (IFN) is key to the pathogenesis of SLE, evidenced by the expression of IFN-stimulated genes (ISGs) in most patients, but the clinical utility of serial ISG assessment remains unknown. With the emergence of IFN-blocking drugs, we aimed to examine IFN status in relation…
-
Journal Article
Clinical associations of cognitive dysfunction in systemic lupus erythematosus
Objective Cognitive dysfunction in SLE is common, but clinical risk factors are poorly understood. This study aims to explore the associations of cognitive dysfunction in SLE with disease activity, organ damage, biomarkers and medications.Methods We performed cross-sectional cognitive assessment…
-
Journal Article
Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
Objective Fas/Fas ligand (FasL) and B cell-activating factor (BAFF) signalling have pivotal roles in SLE pathogenesis. We investigated the clinical associations of serum concentrations of soluble Fas (sFas) and soluble FasL (sFasL) in SLE and their relationship with BAFF.Methods Serum sFas and…
-
Journal Article
Serum IgA autoantibody profiling in systemic lupus erythematosus reveals associations with disease phenotypes
Background Knowledge of the role of IgA isotype autoantibodies in systemic lupus erythematosus (SLE) is lacking. We aimed to explore associations between serum IgA autoantibody profiles and SLE clinical phenotypes using an unbiased approach.Methods 1613 serum IgA autoantibodies were quantified in…
-
Journal Article
Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease characterized by biological and clinical heterogeneity. The interleukin (IL)-1 superfamily is a group of innate cytokines that contribute to pathogenesis in many autoimmune diseases. IL-1β and IL-18 are two members that…
-
Journal Article
Serum autoantibody profiling in systemic lupus erythematosus reveals associations with low disease activity and remission
BackgroundKnowledge of autoantibody specificities and their clinical associations in systemic lupus erythematosus (SLE) is largely limited to panels testing a finite number of autoantibodies. We aimed to explore high-plex serum autoantibody profiles in SLE and examine associations with…
-
Journal Article
Targeting DORIS Remission and LLDAS in SLE: A Review
Abstract Remission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted Definition Of Remission In SLE (DORIS) criteria. Attainment of remission is rare in the clinical setting, thus an alternative, pragmatic…
-
Journal Article
High disease activity persists in adults with childhood-onset lupus
Objective Childhood-onset SLE (cSLE) is often described as more severe than adult-onset disease (aSLE) based largely on cross-sectional studies. We examined differences in disease characteristics, medication use and long-term outcomes between cSLE and patients with aSLE in adulthood using…
-
Journal Article
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study
Abstract Background Anti-ribonucleoprotein (RNP) (auto)antibodies are frequently detected in patients with systemic lupus erythematosus (SLE) although their associations with SLE disease activity remain incompletely understood. We compared patient characteristics, including disease severity…
-
Journal Article
Smith-specific regulatory T cells halt the progression of lupus nephritis
Abstract Antigen-specific regulatory T cells (Tregs) suppress pathogenic autoreactivity and are potential therapeutic candidates for autoimmune diseases such as systemic lupus erythematosus (SLE). Lupus nephritis is associated with autoreactivity to the Smith (Sm) autoantigen and the human…
-
Journal Article
Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study
Abstract Background This study examines the association of standard-of-care systemic lupus erythematosus (SLE) medications with key outcomes such as low disease activity attainment, flares, damage accrual, and steroid-sparing, for which there is current paucity of data. Methods The Asia Pacific…
-
Journal Article
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus
Objective To estimate the prevalence of organ damage (damage) and flare and to examine longitudinal associations between flares and subsequent damage accrual, in patients with systemic lupus erythematosus (SLE).Methods Patients enrolled in the Asia Pacific Lupus Collaboration cohort with ≥3 years…
-
Journal Article
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus
Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological…
-
Journal Article
Informing trial measurement in systemic lupus erythematosus: frequency of domain-specific disease activity in a multinational cohort
Objective To report the prevalence of disease activity in individual SLE organ domains, including prevalence stratified by the most common disease activity cut-off score for clinical trial eligibility (SLE Disease Activity Index 2000; SLEDAI-2K ≥6).Methods We used data from a multinational…
-
Journal Article
Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort
Abstract Background Emerging therapies have the potential to be used in patients with severe refractory systemic lupus erythematosus (srSLE), but no agreed definition of srSLE exists. We evaluated a pilot srSLE definition to assess whether a set of disease activity and treatment thresholds could…
-
Journal Article
‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
Abstract Background The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to…